top of page

Antibody oligonucleotide conjugates as an RNA strategy with the CEO of Avidity Biosciences

Sarah Boyce explains the rationale for using AOCs against muscle disorders like myotonic dystrophy type 1 and DMD, and describes the clinical data Avidity has collected so far.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

NYSE_logo_large_no reg_378x197 (1).png

The NYSE is the world’s largest stock exchange, offering icons and entrepreneurs the opportunity to raise capital and change the world. Our listed companies form a powerful community committed to good governance and societal impact. Industry-leading trading technology, combined with the guidance of experienced traders creates higher market quality for NYSE-market participants

bottom of page